Elan Corp. (ELN) Misses Street's Q2 View
More News related to ELN
- Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
- Notable Analyst Rating Changes 8/29: CBT, NZ, INCY Upgraded; WBD, ENER, WSM Downgraded
- Pre-Open Movers 8/29: Dell Falls On Earnings/Margin Miss, Magma Design (LAVA) Down on Results/Guidance
- Morgan Stanley Starts Elan (ELN) at Overweight
- FDA Issues Complete Response Letter for Paliperidone Palmitate for the Treatment of Schizophrenia
Elan Corporation, plc (NYSE: ELN) reports a Q2 loss of $0.50, versus the analyst estimate of ($0.13). Revenues for the quarter were $245.6 million, versus the consensus of $249.49 million.
Elan Corporation, plc operates as a neuroscience-based biotechnology company primarily in Ireland and the United States.
Related Categories
EarningsStocks Mentioned
+0.18Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
